Traditional Chinese medicine protects against hypertensive kidney injury in Dahl salt-sensitive rats by targeting transforming growth factor-β signaling pathway

Liu, Wei; Li, Yixuan; Xiong, Xingjiang; Chen, Yu-Yi; Qiao, Lumin; Wang, Jie; Su, Xing; Chu, Fuyong; Liu, Hongxu

doi:10.1016/j.biopha.2020.110746

Cited by 10 publications

(9 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to our previous studies, BSJY can promote the expression of the ERK pathway and inhibit the expression of the TNF-α, MCP-1, and IL-6, which would suppress ventricular hypertrophy and inflammatory responses. Furthermore, BSJY may lower BP and protect the target organs of hypertension including the heart and kidney by inhibiting TGF-β1/Smads signaling molecules in spontaneously hypertensive rats [ 54 ]. Based on network pharmacology, 93 active ingredients were predicted for BSJY involving 566 core targets, including 50 direct targets, such as epinephrine receptor, adenosine receptor, endothelin receptor, nitric oxide synthase, and glucose kinases, involved in the regulation of calcium and sodium ion transport, vascular endothelial function, glucose and lipid metabolism, and other related biological processes and signaling pathways [ 55 ].…”

Section: Discussionmentioning

confidence: 99%

Effects of Bushen-Jiangya granules on blood pressure and pharmacogenomic evaluation in low-to-medium-risk hypertensive patients: study protocol for a randomized double-blind controlled trial

Yang

Liu

Xiong

et al. 2022

Trials

Self Cite

View full text Add to dashboard Cite

Introduction Hypertension is one of the most important risk factors for cardiovascular disease, and its control rates remain low worldwide. The most effective strategy is that patients with hypertension should be diagnosed and treated early. Preliminary studies showed that the Bushen Jiangya granule (BSJY) could suppress ventricular hypertrophy and inflammatory responses, lower blood pressure, and protect the target organs of hypertension. We designed a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of BSJY in patients with low-to-medium risk hypertension. Methods and analysis This trial is a one-center, randomized, double-blind, placebo-controlled study. A total of 260 participants will be randomized in a 1:1 ratio to an experimental group (BSJY plus amlodipine) and a control group (placebo plus amlodipine). The trial cycle will last 8 weeks. The primary outcome is the change in 24-h average systolic and diastolic blood pressure. The secondary outcomes include heart rate variability, pharmacogenomic evaluation, improvement in TCM syndrome, and serum pro-inflammatory/anti-inflammatory cytokines between the two groups. The safety of medication will also be evaluated. All the data will be recorded in electronic case report forms and analyzed by SPSS V.22.0. Ethics and dissemination This study has been approved by the Research Ethics Committee of Guang’anmen Hospital, China Academy of Chinese Medical Sciences in Beijing, China (No. 2019-186-KY-01). The participants are volunteers, understand the process of this trial, and sign an informed consent. The results of this study will be disseminated to the public through peer-reviewed journals and academic conferences. Discussion We hypothesize that patients with low-to-medium-risk hypertension will benefit from BSJY. If successful, this study will provide evidence-based recommendations for clinicians. Trial registration Chinese Clinical Trial Registry ChiMCTR1900002876. Registered in November 2019

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of Bushen-Jiangya granules on blood pressure and pharmacogenomic evaluation in low-to-medium-risk hypertensive patients: study protocol for a randomized double-blind controlled trial

Yang

Liu

Xiong

et al. 2022

Trials

Self Cite

View full text Add to dashboard Cite

show abstract

“…According to our previous studies, BSJY can promote the expression of the ERK pathway and inhibit the expression of the TNFα, MCP-1, IL-6, which would suppress ventricular hypertrophy and in ammatory responses. Furthermore, BSJY may lower BP and protect the target organs of hypertension including heart, kidney by inhibiting TGF-β1/Smads signaling molecules in spontaneous hypertensive rats [54] . Based on network pharmacology, 93 active ingredients were predicted for BSJY involving 566 core targets, including 50 direct targets, such as epinephrine receptor, adenosine receptor, endothelin receptor, nitric oxide synthase, glucose Kinases, etc.…”

Section: Discussionmentioning

confidence: 99%

Effects of Bushen-Jiangya granules on blood pressure and pharmacogenomic evaluation in low-to-medium risk hypertension: study protocol for a randomized double-blind controlled trial

Yang¹,

Xiong²,

Zhang³

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

IntroductionHypertension is one of the most important risk factors for cardiovascular disease, and its treatment and control rates are still low worldwide. The most effective strategy is that patients with hypertension should be diagnosed and treated early. Preliminary studies showed that the Bushen Jiangya granule (BSJY) may suppress ventricular hypertrophy and inflammatory responses, lower blood pressure and protect the target organs of hypertension. We designed a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of BSJY in patients with low-to-medium risk hypertension.Methods and analysisThis trial is a one-center, randomized, double-blind, placebo-controlled study. A total of 260 participants will be randomized in a 1:1 ratio to an experiment group (BSJY plus amlodipine) and a control group (placebo plus amlodipine). The trial cycle will last 8 weeks. The primary outcome is blood pressure, which is reduced to a threshold set out in Guiding Principles for Clinical Research of New Chinese Medicines. The secondary outcomes include the change in 24-h average systolic and diastolic blood pressure, heart rate variability, pharmacogenomic Evaluation, improvement in TCM Syndrome, serum pro-inflammatory/anti-inflammatory cytokines, etc. between the two groups. Safety in medication will also be evaluated. All the data will be recorded in electronic case report forms and analyzed by SPSS V.22.0.Ethics and dissemination This study has been approved by Research Ethics Committee of Guang’anmen Hospital,China Academy of Chinese Medical Sciences in Beijing, China (No. 2019-186-KY-01). The participants are volunteers, understand the process of this trial and sign an informed consent. The results of this study will be disseminated to the public through peer-reviewed journals and academic conferences. DiscussionWe hypothesize that patients with low-to-medium risk hypertension will benefit from BSJY. If successful, this study will provide evidence-based recommendations for clinicians.

show abstract

“…HuangQi decoction inhibited protein expressions of α-SMA, collagen I, collagen III and collagen IV through downregulating the expressions of TGF-β1, TGFβRI, TGFβRII, Smad4, Smad2/3, p-Smad2/3 and preserved Smad7 protein expression in the UUO mice ( Zhao et al, 2016 ). Fu-Fang-Jin-Qian-Cao granules, widely used to treat nephrolithiasis, alleviated renal EMT and fibrosis induced by calcium oxalate via downregulating protein expressions of TGF-β1, TGFβRI, TGFβRII, p-Smad3 and p-Smad2, and preserving Smad7 protein expressions ( Liu W. et al, 2020 ). Bu-Shen-Jiang-Ya decoction can relieve renal fibrosis in Dahl salt-sensitive rats by inhibiting protein expressions of TGF-β1 and Smad2/3 ( Liu WR.…”

Section: Natural Products As An Alternative Therapy Against Tubuloint...mentioning

confidence: 99%

TGF-β/Smad Signaling Pathway in Tubulointerstitial Fibrosis

Sun

Zhang

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Chronic kidney disease (CKD) was a major public health problem worldwide. Renal fibrosis, especially tubulointerstitial fibrosis, is final manifestation of CKD. Many studies have demonstrated that TGF-β/Smad signaling pathway plays a crucial role in renal fibrosis. Therefore, targeted inhibition of TGF-β/Smad signaling pathway can be used as a potential therapeutic measure for tubulointerstitial fibrosis. At present, a variety of targeting TGF-β1 and its downstream Smad proteins have attracted attention. Natural products used as potential therapeutic strategies for tubulointerstitial fibrosis have the characteristics of acting on multiple targets by multiple components and few side effects. With the continuous research and technique development, more and more molecular mechanisms of natural products have been revealed, and there are many natural products that inhibited tubulointerstitial fibrosis via TGF-β/Smad signaling pathway. This review summarized the role of TGF-β/Smad signaling pathway in tubulointerstitial fibrosis and natural products against tubulointerstitial fibrosis by targeting TGF-β/Smad signaling pathway. Additionally, many challenges and opportunities are presented for inhibiting renal fibrosis in the future.

show abstract

Traditional Chinese medicine protects against hypertensive kidney injury in Dahl salt-sensitive rats by targeting transforming growth factor-β signaling pathway

Cited by 10 publications

References 61 publications

Effects of Bushen-Jiangya granules on blood pressure and pharmacogenomic evaluation in low-to-medium-risk hypertensive patients: study protocol for a randomized double-blind controlled trial

Effects of Bushen-Jiangya granules on blood pressure and pharmacogenomic evaluation in low-to-medium-risk hypertensive patients: study protocol for a randomized double-blind controlled trial

Effects of Bushen-Jiangya granules on blood pressure and pharmacogenomic evaluation in low-to-medium risk hypertension: study protocol for a randomized double-blind controlled trial

TGF-β/Smad Signaling Pathway in Tubulointerstitial Fibrosis

Contact Info

Product

Resources

About